ADVERSE REACTIONS
Adverse experiences information summarized in the tables below was derived from well-controlled clinical trials conducted in the US and US territories involving 474 patients exposed to MARINOL Capsules. Studies of AIDS-related weight loss included 157 patients receiving dronabinol at a dose of 2.5 mg twice daily and 67 receiving placebo. Studies of different durations were combined by considering the first occurrence of events during the first 28 days. Studies of nausea and vomiting related to cancer chemotherapy included 317 patients receiving dronabinol and 68 receiving placebo.
A cannabinoid dose-related “high” (easy laughing, elation and heightened awareness) has been reported by patients receiving MARINOL Capsules in both the antiemetic (24%) and the lower dose appetite stimulant clinical trials (8%). (See Clinical Trials.)
The most frequently reported adverse experiences in patients with AIDS during placebo-controlled clinical trials involved the CNS and were reported by 33% of patients receiving MARINOL Capsules. About 25% of patients reported a minor CNS adverse event during the first 2 weeks and about 4% reported such an event each week for the next 6 weeks thereafter.
PROBABLY CAUSALLY RELATED: Incidence greater than 1%.
Rates derived from clinical trials in AIDS-related anorexia (N=157) and chemotherapy-related nausea (N=317). Rates were generally higher in the anti-emetic use (given in parentheses).
| *Incidence of events 3% to 10% |
Body as a whole: Asthenia.
Cardiovascular: Palpitations, tachycardia, vasodilation/facial flush.
Digestive: Abdominal pain*, nausea*, vomiting*.
Nervous system: (Amnesia), anxiety/nervousness, (ataxia), confusion, depersonalization, dizziness*, euphoria*, (hallucination), paranoid reaction*, somnolence*, thinking abnormal*. |
PROBABLY CAUSALLY RELATED: Incidence less than 1%.
Event rates derived from clinical trials in AIDS-related anorexia (N=157) and chemotherapy-related nausea (N=317).
| *Incidence of events 0.3% to 1% |
Cardiovascular: Conjunctivitis*, hypotension*.
Digestive: Diarrhea *, fecal incontinence.
Musculoskeletal: Myalgias.
Nervous system: Depression, nightmares, speech difficulties, tinnitus.
Skin and Appendages: Flushing*.
Special senses: Vision difficulties. |
CAUSAL RELATIONSHIP UNKNOWN: Incidence less than 1%.
The clinical significance of the association of these events with MARINOL Capsules treatment is unknown, but they are reported as alerting information for the clinician.
Body as a whole: Chills, headache, malaise.
Digestive: Anorexia, hepatic enzyme elevation.
Respiratory: Cough, rhinitis, sinusitis.
Skin and Appendages: Sweating. |
Postmarketing Experience
Seizure and seizure-like activity have been reported in patients receiving MARINOL Capsules during marketed use of the drug and in clinical trials. (See PRECAUTIONS and OVERDOSAGE.) Reports of fatigue have also been received. A causal relationship between MARINOL Capsules and these events has not been established.
|
REPORTS OF SIDE EFFECTS / ADVERSE REACTIONS RELATED TO MARINOL
Below is a sample of reports where side effects / adverse reactions may be related to Marinol. The information is not vetted and should not be cosidered as verified clinical evidence.
Possible Marinol side effects / adverse reactions in male
Reported by a individual with unspecified qualification from Canada on 2007-01-08
Patient: male weighing 77.1 kg (169.6 pounds)
Reactions: Death
Adverse event resulted in: death
Suspect drug(s):
Marinol
Other drugs received by patient: Morphine; Pantaloc; Metoclop; Docusate; Flomax; Erythropoeitin
Possible Marinol side effects / adverse reactions in 683 month old male
Reported by a consumer/non-health professional from United States on 2007-01-25
Patient: 683 month old male weighing 84.0 kg (184.8 pounds)
Reactions: Haemorrhage, Bladder Cancer
Suspect drug(s):
Marinol
Other drugs received by patient: Aleve
Possible Marinol side effects / adverse reactions in male
Reported by a physician from Canada on 2007-02-27
Patient: male weighing 69.6 kg (153.1 pounds)
Reactions: Hallucination, Auditory, Drug Dependence
Suspect drug(s):
Marijuana
Dosage: daily dose: unknown
Indication: Ill-Defined Disorder
Marinol
Dosage: daily dose: 20 milligram(s)
Administration route: Oral
Indication: Neuralgia
Start date: 2005-03-14
End date: 2005-03-21
Other drugs received by patient: Ranitidine; Flexeril
|
